Tempus AI’s TEM stock has surged nearly 13% since its second-quarter 2025 earnings release. The quarter saw strong top-line ...

Over the past two years, one of the most interesting healthcare companies to go public is none other than Tempus AI (NASDAQ: ...

The collaboration will fund early-stage clinical development of SB-4826, CIT’s first-in-class SUMO E1 inhibitor, for patients ...

Tempus AI, Inc. Class A (($TEM)) has held its Q2 earnings call. Read on for the main highlights of the call. Tempus AI, Inc. Class A recently held ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Tempus AI achieves strong revenue growth and beats expectations, but ongoing losses and execution risks temper enthusiasm.

Magnus Tempus 360—a visionary initiative dedicated to forging new curatorial and collaborative pathways across the Mediterranean.

In a report released today, Rachel Vatnsdal from J.P. Morgan maintained a Hold rating on Tempus AI, Inc. Class A, with a price target of $60.00. The company’s shares closed last Friday at $60.87. Take ...

In a report released on August 8, Subbu Nambi from Guggenheim reiterated a Buy rating on Tempus AI, Inc. Class A, with a price target of $75.00. The company’s shares closed last Friday at $60.87.

Tempus AI, Inc. (NASDAQ:TEM) investors will be delighted, with the company turning in some strong numbers with its latest results. Results overall were solid, with revenues arriving 5.7% better than ...

A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled “Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate ...